Serum lipocalin-2 levels are increased in patients with psoriasis.

Authors :: Kamata M
Tada Y
Tatsuta A
Kawashima T
Shibata S
Mitsui H
Asano Y
Sugaya M
Kadono T
Kanda N
Watanabe S
Sato S
Source :: Clinical and experimental dermatology [Clin Exp Dermatol] 2012 Apr; Vol. 37 (3), pp. 296-9. Date of Electronic Publication: 2012 Feb 02.
Publication Year :: 2012
Abstract: The protein lipocalin (LCN)-2 is known to be related to insulin resistance, obesity and atherosclerotic diseases. Psoriasis is an inflammatory skin disease related to metabolic syndrome. The aim of this study was to examine the relationship between serum LCN2 levels and indicators for metabolic syndrome and inflammatory cytokine levels in patients with psoriasis. Serum LCN2 levels were measured in patients with psoriasis, atopic dermatitis (AD) or bullous pemphigoid (BP), and compared with those of healthy controls. Serum LCN2 levels were also compared with several indicators for metabolic syndrome, and with serum levels of interleukin (IL)-6 and tumour necrosis factor (TNF)-α, two markers of inflammation. Serum LCN2 levels in patients with psoriasis were significantly higher than those of healthy controls, but there was no significant correlation between serum LCN2 and body mass index. Serum LCN2 levels also correlated with serum IL-6 and TNF-α levels in patients with psoriasis. Serum LCN2 levels are a general indicator for increased inflammation in the patients with psoriasis.<br /> (© The Author(s). CED © 2012 British Association of Dermatologists.)